KyungDong Pharm home
Prescription Medicines

Aloscan Tab.

Product Category
hair solvent
Active Ingredients
finasteride
Appearance
Octagon-shaped, yellow-brown film-coated tablet with biconvex sides.
View Regulatory Information on the MFDS Portal ↗
1. Ingredient content
1 tablet
- Active ingredient: Finasteride (USP) --- 1.0mg
- Additives (animal-derived ingredients): Magnesium stearate (beef, beef tallow, pork, pork), lactose hydrate (cow, milk)
- Additives (tar colorant): Blue No. 2 Aluminum Lake
- Other additives: light anhydrous silicic acid, microcrystalline cellulose, Opadry Pink (85G44100), pregelatinized starch, crospovidone, floxamer 407, hydroxypropyl cellulose

2. Effectiveness
Treatment of male pattern baldness (androgenic alopecia) in adult men (18 to 41 years old)

3. Dosage and dosage
Generally, finasteride is administered orally at 1 mg once a day, and can be administered regardless of meals. There is no evidence that increasing the dose increases effectiveness. Generally, you need to take it for more than 3 months to see the treatment effect, and it is recommended to take it continuously to maintain the treatment effect. Duration and effectiveness of treatment should be continuously evaluated. If you stop taking it, the treatment effect will disappear within 12 months.

4. Precautions for use
1. Warning
1) This drug should not be administered to pediatric patients or women (refer to the sections on administration to children and administration to pregnant women).
2) If a pregnant woman or a woman who may be pregnant touches the broken pieces of this medicine, this medicine may be absorbed through the skin and may pose a risk to the male fetus. Therefore, pregnant women or women who may be pregnant should not touch the broken pieces of this medicine. Since the surface of this medicine is coated, it does not come into contact with the active ingredient when the tablet is handled normally in an unbroken state (refer to the section on administration to pregnant women).
3) Mood swings and depression
Depressed mood and depression were reported in patients administered 1 mg of finasteride, and in smaller cases, mood swings including suicidal thoughts were reported. Patients should be observed for psychiatric symptoms, and if these symptoms occur, finasteride should be discontinued and a healthcare professional should be consulted.

2. Do not administer to the following patients.
1) Pregnant women or women who may be pregnant: 5α-reductase inhibitors such as this drug inhibit the conversion of testosterone to dihydrotestosterone, so if a pregnant woman takes this drug, it may cause abnormalities in the external genitalia of the male fetus. Therefore, if you take this drug during pregnancy or become pregnant while taking this drug, the patient must be informed of the potential risk to the male fetus (see warnings and administration to pregnant women). When administered to female rats at low doses during pregnancy, abnormalities in the external genitalia of male offspring occurred.
2) Patients who exhibit hypersensitivity to this drug or its components
3) Patients taking 5mg of this drug or other 5α-reductase inhibitors due to benign prostatic hyperplasia, etc.
4) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

3. Administer with caution to the following patients.
Since this drug is extensively metabolized in the liver, it should be administered with caution to patients with abnormal liver function.

4. Adverse reactions
1) In three controlled clinical trials over 12 months in which 1 mg of this drug was administered to patients with androgenetic alopecia, 1.4% of patients in the treatment group dropped out of the clinical trial due to adverse reactions that were reported to be possibly, significantly, or clearly related to the drug, and 1.2% of patients in the treatment group and 0.9% of patients in the placebo group dropped out of the clinical trial due to adverse reactions related to sexual function due to drug administration (placebo group: n=1.6% of 934).

* Table 1: Refer to attached document

Among the adverse reactions that occurred at a frequency of 1% or more when this drug or placebo was administered for 12 months, the adverse reactions that were reported to be possibly related, significantly related, or clearly related to the drug are shown in Table 1.

Comprising the results of the adverse reaction analysis, 36 (3.8%) of the 945 patients who received this drug and 20 (2.1%) of the 934 patients who received the placebo experienced one or more adverse reactions related to sexual function (p = 0.04). When medication was discontinued due to adverse reactions related to sexual function, these adverse reactions disappeared in all patients after discontinuation of medication, and in most patients who continued taking the medication, the adverse reactions disappeared.

In a clinical trial in which healthy men were administered 1 tablet of this drug or placebo once daily for 48 weeks, the median reduction in ejaculate volume was 0.3 mL (-11%) and 0.2 mL (-8%), respectively. In two other clinical trials in which a 5-fold dose (5 mg/day) of this drug was administered, the median amount of ejaculate reduction was significantly decreased by about 0.5 mL (-25%) compared to the placebo group, but this phenomenon recovered when the drug was discontinued. The prevalence of breast tenderness/enlargement, hypersensitivity reaction, and testicular pain reported in clinical trials was similar in the placebo group and the placebo group.

2) In a 4-year placebo-controlled clinical trial (PLESS, Proscar Long-Term Efficacy and Safety Study) in which 5 mg of this drug was administered, a 4-year safety evaluation was conducted on 3,040 patients with benign prostatic hyperplasia (regardless of the presence or absence of symptoms) aged 45 to 78 years. 3.7% (57 patients) treated with this drug 5 mg and 2.1% (32 patients) treated with placebo discontinued treatment due to adverse reactions related to sexual function. The most frequently reported adverse reactions were adverse reactions related to sexual function. In the 4-year clinical trial, adverse reactions occurred at a higher frequency than placebo, and the occurrence rate at 5 mg of this drug was more than 1%. Adverse reactions that were considered possibly, significantly, or clearly related to the drug by the clinical trial researchers are shown in Table 2 below. There was no significant difference in the rates of erectile dysfunction, decreased libido, and ejaculatory disorders between treatment groups in the 2 to 4 year clinical trial.

* Table 2: Refer to attached document

The adverse reaction profile was similar in a 1-year placebo-controlled, phase 3 clinical trial and a 5-year open-label, extended trial in which 5 mg of this drug was administered to patients with benign prostatic hyperplasia. There was no increase in adverse reactions as the administration period of 5 mg of this drug increased. Reports of new drug-related sexual adverse reactions decreased during the treatment period.

In a placebo and positive control clinical trial conducted on 3,047 patients for 4 to 6 years, 4 cases of breast cancer occurred in the group administered 5 mg of this drug, and no cases occurred in the placebo group or positive control group. In a separate placebo-controlled clinical trial conducted for 4 years on 3,040 patients, 2 cases of breast cancer occurred in the placebo group and no cases occurred in the 5 mg treatment group. In a 7-year placebo-controlled clinical trial (Prostate Cancer Prevention Trial, PCPT) involving 18,882 healthy men, one case of breast cancer occurred in the 5 mg treatment group and one case of breast cancer occurred in the placebo group. There are post-marketing reports of male breast cancer at doses of 1 mg and 5 mg. The association between long-term use of this drug and male breast neoplasms is currently unknown. The PCPT trial was a 7-year, randomized, double-blind, placebo-controlled trial involving 18,882 men aged 55 years or older with normal digital rectal examination and PSA levels ≤3.0 ng/mL. Men received 5 mg of this drug or placebo once daily. Patients underwent digital rectal examination and PSA evaluation every year, and biopsies were performed when PSA was elevated or the digital rectal examination was abnormal, and at the end of the clinical trial. The incidence of Gleason grade 8 to 10 prostate cancer was higher in men receiving this drug (1.8%) compared to men receiving placebo (1.1%). Similar results were observed in a 4-year placebo-controlled clinical trial of another 5α-reductase inhibitor (dutasteride) for Gleason grade 8 to 10 prostate cancer (1% dutasteride vs. 0.5% placebo). The clinical significance in men receiving 1 mg of this drug is unknown.

3) The following adverse reactions were additionally reported after marketing. Because these adverse reactions are voluntarily reported from an unspecified population, it is generally not possible to reliably estimate their incidence or establish a causal relationship with drug exposure.

- Immune system: hypersensitivity reactions such as rash, itching, hives and angioedema (including swelling of the lips, tongue, throat and face)

- Musculoskeletal and connective tissue disorders: muscle pain, myasthenia

- Mental system: depression, suicidal thoughts, decreased libido that persists after discontinuation of administration, anxiety

- Reproductive system and breasts: breast tenderness and enlargement; testicular pain; Hematospermia; Sexual dysfunction (erectile dysfunction, ejaculation disorder) and orgasm disorder that persist after discontinuation of administration; Male infertility and/or poor semen quality. Normalization or improvement in semen quality has been reported after discontinuation of treatment with this drug; male breast cancer

- Gastrointestinal disorders (heartburn), dizziness, headache, palpitations, increased liver enzyme levels

5. General precautions

1) Doctors instruct patients to promptly report any breast changes, including lumps, pain, nipple discharge, breast enlargement, tenderness, and neoplasms.

2) Doctors should inform patients that ejaculation volume may decrease in some patients during treatment with this drug. Although this reduction in ejaculate volume does not appear to interfere with normal sexual function, erectile dysfunction and decreased libido may occur in patients treated with this drug.

3) In a PCPT clinical trial in men aged 55 years or older with a normal digital rectal examination and PSA level ≤3.0 ng/mL, who took 5 mg per day of this drug for 7 years, the risk of Gleason grade 8 to 10 prostate cancer was increased (finasteride 1.8% vs. placebo 1.1%). Other 5α-reductase inhibitors (dutasteride) (1%) Similar results were observed in a 4-year placebo-controlled clinical trial of dutasteride (dutasteride vs 0.5% placebo). 5α-reductase inhibitors may increase the risk of developing high-grade prostate cancer, but it has not been established whether this is due to the effect of 5α-reductase inhibitors to reduce prostate volume or other factors that influence the results of these studies.

6. Interaction

No clinically significant drug interactions have been identified. It is known that this drug does not affect the CYP-450 drug-metabolizing enzyme system. Clinical trials have been conducted to investigate the interaction of this drug with antipyrine, digoxin, glyburide, glibenclamide, propranolol, theophylline, and warfarin, but no significant interactions have been observed. Although no studies have been conducted on interactions, doses of 1 mg or more of this drug during clinical trials have been used against acetaminophen, acetylsalicylic acid, α-blockers, analgesics, ACE inhibitors, It has been used in combination with anticonvulsants, benzodiazepines, β-blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (NSAIDs), and quinolone antibacterial agents without clinically significant adverse reactions.

7. Administration to pregnant women

1) This drug should not be administered to women.

2) When this drug was administered to pregnant rats in a dosage range of 100 mcg/kg/day to 100 mg/kg/day (5 to 5,000 times the usual dose in humans), the incidence of hypospadias in male littermates increased to 3.6 to 100% in proportion to the administered dose. When doses of 30 mcg/kg/day or more (more than 1.5 times the usual dose in humans) were administered to pregnant rats, the weight of the prostate and seminal vesicles was reduced, foreskin separation was delayed, and male offspring with temporary nipple development were produced. Additionally, when doses of 3 mcg/kg/day or more (1/4 of the usual dose in humans) were administered to pregnant rats, male offspring were produced with a reduced distance between the anus and genitals. It was found that these effects were induced in male rats between 16 and 17 days of pregnancy. The above changes are the pharmacological effects of drugs belonging to the type II 5α-reductase inhibitor class and are similar to those reported in male infants with congenital type II 5α-reductase deficiency. No abnormal findings were found in female littermates who had been exposed to various doses of this drug in utero.

3) No abnormal developmental findings were observed in the first generation male and female offspring produced by mating male rats administered this drug (80 mg/kg/day, 488 times the usual dose in humans) with female rats that did not receive this drug. When a dose of 3 mg/kg/day (150 times the usual dose in humans) is administered during late pregnancy and lactation, the first generation male offspring Fertility was slightly reduced, but there was no effect on female offspring. No evidence of teratogenic effects was found in rabbit fetuses exposed in utero to a dose of 100 mg/kg/day (5000 times the usual dose in humans) between days 6 and 18 of pregnancy. However, in this study, no exposure to this drug occurred during reproductive development, so effects on male reproductive organs could not be expected.

4) The effects of exposure to this drug in utero during embryonic and fetal development were evaluated in rhesus monkeys, an animal model that allows better prediction of effects in human development compared to rats or rabbits (20 to 100 days of gestation). When pregnant monkeys were administered intravenously at a dose of 800 ng/day (more than 250 times the highest dose that could be exposed to women from the semen of men taking a dose of 1 mg/day), no abnormal findings were observed in male fetuses. To determine whether it is appropriate to use a monkey model to predict effects on the development of human fetuses, 2 mg/kg/day of this drug was orally administered to pregnant monkeys, and abnormal findings in the external genitalia of male fetuses were observed. No other abnormalities were found in male fetuses, and no abnormalities related to this drug were observed in female fetuses at any dose.

8. Administration to nursing mothers

This medication should not be given to women. It is not known whether this medication is excreted in milk.

9. Administration to children

This drug should not be administered to pediatric patients. Safety and efficacy in children have not been established.

10. Administration to elderly people

This drug has not been clinically studied for effectiveness in patients over 65 years of age. Based on the pharmacokinetic data from the administration of 5 mg of this drug, no dose adjustment is necessary when administering this drug to the elderly. However, the effectiveness of this drug in elderly people has not been established.

11. Effect on clinical test values

In clinical trials of this drug conducted on patients aged 18 to 41 years, the average serum prostate-specific antigen (PSA) value decreased from 0.7 ng/mL to 0.5 ng/mL at 12 months. When this drug was used in elderly men with benign prostatic hyperplasia, PSA levels decreased by approximately 50%. If your PSA level is tested while taking this medication, you should consider appropriately interpreting the results.

12. Treatment in case of overdose

During clinical trials, no adverse reactions occurred even when 400 mg of this drug was taken once or at a dose of 80 mg/day for 3 months. Until additional information is collected, there are no specific recommended treatment methods for overdose of this drug. When administered orally once at a dose of 1,500 mg/m2 (500 mg/kg) to male and female mice, or when administered once orally to male and female rats at doses of 2,360 mg/m2 (400 mg/kg) and 5,900 mg/m2 (1000 mg/kg), respectively. Significant mortality was observed.

13. Precautions for storage and handling

1) Keep out of reach of children.

2) Be careful not to change it into another container as it may cause an accident or is undesirable in terms of maintaining quality.

14. Others

1) Carcinogenicity: It did not show tumorigenicity when administered to male rats at a dose of 160 mg/kg/day and to female rats at a dose of up to 320 mg/kg/day for 24 months. These doses correspond to 888 and 2,192 times the systemic exposure of men administered the recommended human dose of 1 mg/day of this drug, respectively. In a 19-month carcinogenicity study using CD-1 mice, a statistically significant (p≤0.05) increase in testicular Leydig cell adenoma was observed at a dose of 250 mg/kg/day (1,824 times the human exposure). It was observed. In mice administered a dose of 25 mg/kg/day (184 times the human exposure dose) and rats administered a dose of 40 mg/kg/day (312 times the human exposure dose), proliferation of Leydig cells and an increase in plasma LH levels (2 to 3 times that of the placebo group) were confirmed.

2) No mutagenicity was observed in the in vitro bacterial mutation test, mammalian mutation test or in vitro alkaline elution test. In an in vitro chromosomal abnormality test, when a high concentration (450 ~ 550 μmol) of this drug was administered to Chinese hamster ovary cells, chromosomal abnormalities slightly increased.

3) Impairment of fertility In sexually mature male rats, 80 mg/kg/day (488 times the human exposure dose) had no significant effect on reproductive performance after 6 or 12 weeks. However, when administered continuously for up to 24 or 30 weeks, a clear decrease in reproductive and fertilizing abilities and a significant decrease in the weight of seminal vesicles and prostate were observed. All these changes were reversible within 6 weeks of stopping treatment. The decrease in reproductive function in rats administered this drug is a secondary result of the failure to form a seminal plug due to the effect on the accessory sexual organs (prostate and seminal vesicles). The seminal fluid is essential for normal fertility in rats and is not relevant to humans.

5. How to save
Store in an airtight container at 15-30℃, avoiding moisture.

6. Packaging unit
30 tablets/box (10 tablets/PTP×3)

7. Period of use
36 months from date of manufacture

Product Updates

Total 2items

No.Product NameDetailsDate of ChangeDownload
2Aloscan Tab.Precautions for use2024.11.07PDF24_200705313_Alloscan Tablet_Precautions for Use (Change).pdf
1Aloscan Tab.Precautions for use2021.02.16HWPContents of permission change order_Finasteride_tablet_1mg.hwp